Establishment Labs (NASDAQ:ESTA) Stock Gets Price Target Trim from TD Cowen

Establishment Labs (NASDAQ:ESTA) had its target price lowered by TD Cowen from $117.00 to $95.00 in a report issued on Monday,Benzinga reports. The brokerage currently has a buy rating on the stock.

ESTA has been the subject of several other research reports. Mizuho lifted their price target on Establishment Labs from $100.00 to $105.00 and gave the company an “outperform” rating in a research note on Wednesday, July 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Establishment Labs in a report on Monday, September 21st. Citigroup upgraded Establishment Labs from a “neutral” rating to a “buy” rating and set a $92.00 price target on the stock in a research report on Thursday, August 13th. Stifel Nicolaus set a $85.00 price objective on Establishment Labs and gave the company a “buy” rating in a report on Wednesday, October 14th. Finally, BTIG Research reissued a “buy” rating and issued a $103.00 price objective on shares of Establishment Labs in a report on Tuesday, September 1st. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $96.11.

Establishment Labs Stock Up 3.0%

ESTA opened at $68.97 on Monday. Establishment Labs has a fifty-two week low of $47.00 and a fifty-two week high of $97.59. The company has a debt-to-equity ratio of 12.11, a quick ratio of 2.52 and a current ratio of 3.84. The company has a fifty day moving average of $67.38 and a two-hundred day moving average of $72.36. The stock has a market capitalization of $2.06 billion, a price-to-earnings ratio of -52.65 and a beta of 1.06.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.05). Establishment Labs had a negative return on equity of 196.69% and a negative net margin of 15.82%. The firm had revenue of $67.54 million during the quarter, compared to analyst estimates of $65.79 million. During the same quarter last year, the company posted ($0.57) EPS. The company’s revenue was up 31.7% on a year-over-year basis. On average, research analysts expect that Establishment Labs will post -1.08 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Arizona State Retirement System increased its stake in shares of Establishment Labs by 5.6% in the 2nd quarter. Arizona State Retirement System now owns 5,057 shares of the company’s stock worth $434,000 after acquiring an additional 268 shares during the last quarter. HighTower Advisors LLC raised its holdings in shares of Establishment Labs by 3.2% during the 2nd quarter. HighTower Advisors LLC now owns 9,517 shares of the company’s stock worth $817,000 after acquiring an additional 293 shares during the period. Integrated Wealth Concepts LLC acquired a new position in shares of Establishment Labs during the 2nd quarter valued at about $32,000. KBC Group NV acquired a new position in shares of Establishment Labs during the 1st quarter valued at about $28,000. Finally, Northwestern Mutual Wealth Management Co. acquired a new position in shares of Establishment Labs during the 2nd quarter valued at about $43,000. 72.91% of the stock is currently owned by institutional investors and hedge funds.

About Establishment Labs

Establishment Labs Holdings Inc is a medical technology company focused on women’s health and the breast aesthetics market. The company develops, manufactures and commercializes breast implants and related technologies designed for breast augmentation, reconstruction and revision procedures.

Its product portfolio includes the Motiva line of breast implants, which incorporates the company’s proprietary implant materials, surface technologies and design features. Establishment Labs also offers Motiva Flora tissue expanders for use in breast reconstruction and has developed Mia Femtech, a minimally invasive breast enhancement procedure intended to provide a less invasive alternative to traditional augmentation techniques.

Founded in 2004, Establishment Labs is headquartered in Costa Rica and serves physicians, hospitals and patients in international markets.